Naveen Pemmaraju: PVO combination program for frontline CLL treatment
Naveen Pemmaraju shared a post on X:
” ASH Kudos to Dr. Nitin Jain for an important abstract PVO combination program for patients for treatment frontline CLL, leusm, BTKi, Pirtobrutinib.
Number=74; very high rates of BMUMRD6 at 6 and 12 mo of combo treatment.
Authors: Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Patrick K. Reville, Jan A. Burger, Vanthana Bharathi, Himachandana Atluri, Hua-Jay J Cherng, Alex Bataller, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Kelly S. Chien, Musa Yilmaz, Naveen Pemmaraju, Naval Daver, Fadi G. Haddad, Yesid Alvarado Valero, Jo Ishizawa, Guillermo Montalban-Bravo, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Deepa Sampath, Varsha Gandhi, Michael J. Keating, Hagop M. Kantarjian, William G. Wierda.”
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023